系统性轻链氨基粉症预后和治疗的最新进展
1National Amyloidosis Centre, University College London, London, UK.
Future cardiology
|July 12, 2025
概括
系统性轻链氨基粉症 (AL) 是一种罕见的血细胞疾病. 新的疗法准了粉样蛋白沉积物,为改善结果提供了希望,特别是在心脏病患者中.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 系统性轻链 (AL) 氨基粉症是一种罕见的血细胞疾病.
- 异常的免疫球蛋白自由光链错误地折叠成粉样纤维,沉积在组织中.
- 心脏参与是AL氨基粉症预后的主要决定因素.
研究的目的:
- 审查ALamyloidosis的诊断和治疗方面的进展.
- 突出多模式心脏成像的作用.
- 讨论针对纤维细胞去除的新型抗粉样蛋白疗法.
主要方法:
- 关于AL氨基粉症病理生理学,诊断和治疗的当前文献的综述.
- 强调心脏成像技术的进步.
- 讨论新兴的抗粉样蛋白疗法.
主要成果:
- 多模式心脏成像改善了诊断和治疗监测.
- 准血细胞克隆已经改变了治疗.
- 针对粉样纤维素清除的新疗法正在开发中.
结论:
- 系统性AL氨基粉症治疗已经显著进展.
- 心脏成像在管理AL氨基粉症中起着至关重要的作用.
- 新兴的疗法通过清除粉样蛋白沉积物,对疾病回归有希望.
相关概念视频
Nephrotic Syndrome II : Assessment and Medical Management
23
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
23
Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40


